Company news
Neuropace, Inc. (NASDAQ:NPCE) news
Every Neuropace, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
July 28, 2026
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosur...
May 29, 2026
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
May 29, 2026
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
May 12, 2026
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUT...
April 27, 2026
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
April 10, 2026
NeuroPace to Present at the Leerink Global Healthcare Conference
March 5, 2026
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
March 3, 2026
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
February 20, 2026
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
January 13, 2026
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 31, 2025
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
December 17, 2025
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
December 8, 2025
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
December 2, 2025
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
November 24, 2025
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
November 4, 2025
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
October 22, 2025
NeuroPace to Participate in Upcoming Healthcare Conferences
August 28, 2025
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
August 12, 2025
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
August 1, 2025
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
July 29, 2025
NeuroPace Announces Strategic CFO Transition
June 24, 2025
NeuroPace Secures Up to $75 Million in Debt Financing
June 4, 2025
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
May 27, 2025
NeuroPace Reports First Quarter 2025 Financial Results
May 13, 2025
NeuroPace Provides Update on Tariff Status
April 14, 2025
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
April 8, 2025
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Me...
April 3, 2025
NeuroPace Announces Refocusing of Product Portfolio
April 2, 2025
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
March 4, 2025
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
March 3, 2025
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
March 3, 2025
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
February 20, 2025
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
February 19, 2025
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
February 18, 2025
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
February 14, 2025
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
February 13, 2025
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurolog...
February 3, 2025
NeuroPace Issues 2025 Financial Guidance Targets
January 28, 2025
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
January 8, 2025
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
NeuroPace to Host Investor Day on January 28th in New York City
December 12, 2024
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
December 4, 2024
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
December 3, 2024
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
November 12, 2024
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
November 4, 2024
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
October 22, 2024
NeuroPace Continues to Strengthen Management Team
October 16, 2024